'-AZIDO-3'-DEOXYTHYMIDINE
'-AZIDO-3'-DEOXYTHYMIDINE
'-DIDEOXYINOSINE
A-C
A-D
AZT
AZT
AZT
AZT
AZT
AZT
AZT RESISTANCE
AZT RESISTANCE
AZT RESISTANCE CONFERRED
AZT RESISTANCE SELECTABLE
AB
AB
AB
AB IMMUNITY
AB PROTECTION
AB-DEPENDENT CELLULAR CYTOTOXICITY
ABBREVIATION
HUMAN           IMMUNODEFICIENCY VIRUS ABBREVIATION
ANTIBODIES
ANTIBODIES
ANTIBODIES
ANTIBODIES
ANTIBODIES
ANTIGENIC DRIFT
ANTIGENIC DRIFT
B-CELL IMMUNITY
B-CELL IMMUNITY
B-CELL IMMUNITY
B-CELL IMMUNITY
B-CELL IMMUNITY
B-CELL-SELECTED ANTIGENIC DRIFT
CD4
CD4-BINDING SITE
CD4-INDUCED
CD4-INDUCED EPITOPE
CTL EPITOPE
CURRENT VERSION
QUASI CURRENT VERSION
CY
DIALIGN2
DIMMOCK
EVOLVER PROGRAM
PAML PACKAGE EVOLVER PROGRAM
F MUTATION
F215
FASTA
FALSE POSITIVE PERCENTAGE
FALSE-POSITIVE TESTING
FITCH GROUP
FITCH GROUP
FITCH GROUP
GPGKAF
GPGKTF
GPGKVF
GPGRAF
GPGRAF MOTIF
GPGRAF MOTIF
GPGRTF
GPGRVF
GOJOBORI
H3 HEMAGGLUTININ QUASI
H3 SEROTYPE
H3 SEROTYPE
H3 VIRUS
H333
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HEMAGGLUTININ
HA T-CELL EPITOPE
HA CODON
HA ESCAPE MUTANT
HA SURFACE
HA SURFACE
HA TRIMER
HA VARIANT
HUMAN           IMMUNODEFICIENCY VIRUS
HUMAN           IMMUNODEFICIENCY VIRUS
HUMAN           IMMUNODEFICIENCY VIRUS
HUMAN           IMMUNODEFICIENCY VIRUS
HUMAN           IMMUNODEFICIENCY VIRUS
HUMAN           IMMUNODEFICIENCY VIRUS
HUMAN           IMMUNODEFICIENCY VIRUS
HIV ANTIGENIC DRIFT
HIV BREAKTHROUGH INFECTION
HIV PROTEIN
HIV QUASISPECY
HIV STRAIN RF
HIV VACCINE
HIV VIRUS
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
HIV-1 RT
HIV-1 RT
HIV-1 RT SEQUENCE
HIV-1 GP120
HIV-1 GP120
HIV-1 GP120
HIV-1 GP120 SEQUENCE
HIV-1 REVERSE TRANSCRIPTASE
VIRAL SEQUENCE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
I225
I345
I424
ILE
JUKES-CANTOR
L41
L453
MAJOR HISTOCOMPATIBILITY           COMPLEX
MAJOR HISTOCOMPATIBILITY           COMPLEX
MINIMUM SEQUENCE
N MUTATION
N-Î‘1
N295
N67
NIH
NUCLEOTIDE SEQUENCE
PAML PACKAGE
PILEUP
PHE
PHYLOGENETIC ANALYSIS
PHYLOGENY
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI
QUASI ALGORITHM
QUASI ALGORITHM
QUASI FILE CONVERTER PERL SCRIPT
QUASI SOFTWARE
QUASI TEST
QUASI--THE SELECTION MAPPING
R70
RNA VIRUS
REVERSE TRANSCRIPTASE
REVERSE TRANSCRIPTASE
REVERSE TRANSCRIPTASE
REVERSE TRANSCRIPTASE
RT CODON
RT FUNCTION
RT MUTATION
RT QUASISPECIATION
RT SELECTION MAP
RT SEQUENCE
S CALCULATION
S POINT MUTATION
SELECTION MAP
SELECTION MAP
HIV-1 GP120 SELECTION MAP
INFLUENZA SELECTION MAP
SHANNON CALCULATION
SHANNON INFORMATION CONTENT
S
T-CELL EPITOPE
T-CELL EPITOPE
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY
T-CELL IMMUNITY ESCAPE VARIANT
T387
TYR
TYR
TYR
TYR
V270
W210
Y215
ACID
ACID REPLACEMENT
ADVANTAGE CONFERRED
AFFECTING HA VARIATION
AFFECTING HIV QUASISPECIATION
AGGREGATE
AGGREGATE
AGGREGATION
ALGORITHM
ALGORITHM
ALIGNMENT GAP
ALIGNMENT GAP
ANCESTRAL SEQUENCE
ANTI-RT DRUG
ANTI-RT TREATMENT
ANTI-GP120 AB
ANTIBODY
ANTIGENIC DRIFT
ANTIGENIC DRIFT
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE B
ANTIGENIC SITE C
ANTIGENIC SITE D
ANTIGENIC SITE D
ANTIGENIC SITE D
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
A-C ANTIGENIC SITE
A-D ANTIGENIC SITE
ANTIGENICALLY DRIFTING PROTEIN
APPELLATION
ASSEMBLED HA PROTEIN
ATT
BINOMIAL DISTRIBUTION
CARBOHYDRATE GROUP
CARBOHYDRATE-BUILDING MODEL
GP120 CARBOHYDRATE-BUILDING MODEL
CELLULAR TROPISM
CLASSIC EXAMPLE
ANTIGENICALLY DRIFTING PROTEIN CLASSIC EXAMPLE
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
CODON
COMMUN
COMPETITION-GROUP EPITOPE
CONSENSUS CODON
CONSENSUS CODON
CONSENSUS CODON
CONSENSUS CODON
CONSIDERATION
CTA
CTA
CTA
CTG
CTG
CTG CODON
CTT
CYSTINE
DECADES-OLD PUZZLE
DEMARCATION
ANTIGENIC SITE DEMARCATION
DESCENDING ORDER
DETERMINANT
INFLUENZA A--I DETERMINANT
DETERMINATION
DISADVANTAGE
DISADVANTAGE
VALINE DISADVANTAGE
DISEASE VIRUS
DISTRIBUTION
EMPIRICAL REPLACEMENT
ENVELOPE SURFACE GLYCOPROTEIN--THE
EPITOPE
EPITOPE
EPITOPE
ESCAPE MUTANT
ESCAPE VARIANT
ESTIMATOR
EXAMPLE CASE
EXECUTABLE VERSION
QUASI SOFTWARE EXECUTABLE VERSION
EXEMPLARY CODON
EXPECTED S
FACTOR
FAILURE RATE
FALSE-POSITIVE PERCENTAGE
FALSE-POSITIVE
FLU
GLYCOPROTEIN
GLYCOPROTEIN
GOV
GP120
GP120
GP120
GP120
GP120
GP120
GP120
GP120
GP120
GP120
GP120 MOLECULE
GP120 MOLECULE
GP120 MONOMER
GP120 MONOMER
GP120 QUASISPECIATION
GP120 RESIDUE
GP120 SURFACE
GP120 THREE-DIMENSIONAL STRUCTURE
GP120 TRIMER INTERFACE
GTT
HELPER T-CELL EPITOPE
HEMAGGLUTININ
HEMAGGLUTININ
HISTOCOMPATIBILITY COMPLEX
HISTOCOMPATIBILITY COMPLEX
HOST CELL TYPE
HTTP
HUMAN-INFECTIVE INFLUENZA
I TH FRACTION
IDENTIFICATION
POSITIVE SELECTION IDENTIFICATION
IGNORING PHYLOGENY
IMMUNODEFICIENCY VIRUS
IMMUNODEFICIENCY VIRUS
IMMUNOLOGICALLY DISTINCT MEMBER
VIRAL QUASISPECY IMMUNOLOGICALLY DISTINCT MEMBER
IN VIVO RT
INCLUDING MHC PRESENTATION
INDIVIDUAL CODON
INDIVIDUAL CODON
REPLACEMENT MUTATION INDIVIDUAL CODON
INDIVIDUAL REPLACEMENT
INFECTION
INFECTION
INFLUENZA
INFLUENZA
INFLUENZA
INFLUENZA
INFLUENZA
INFLUENZA
INFLUENZA A--I
INFLUENZA VACCINE
INTERPRETATION
INTRA-PATIENT VIRAL DIVERSITY
ISOLEUCINE
LABORATORY MUTATION
LANL
LENGTH INTERVAL
LEUCINE
LIKELIHOOD PHYLOGENY
LOWER-THAN-EXPECTED
LOWERCASE LETTER
LYSINE
MAXIMUM
MAXIMUM
MAXIMUM
MODAL CODON
MODEL SYSTEM
MONOCLONAL AB
MONOCLONAL ANTIBODY
MOST-TYPICAL CODON
MOST-TYPICAL CODON
MOTIF
MULTIVALENT VACCINE
MUTATED VIRAL SEQUENCE
MUTATION RATIO
MUTATION RATIO
MUTATIONAL HISTORY
MUTATIONAL SPACE
NEGATIVE SELECTION
NEGATIVE SELECTION
NEGATIVE SELECTION
NEGATIVE SELECTION
NEUTRAL JUKES-CANTOR EVOLUTION
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT FREQUENCY
NEUTRAL DRIFT HYPOTHESIS
NEUTRAL DRIFT PARAMETER
NEUTRAL DRIFT TESTING
QUASI NEUTRAL DRIFT TESTING
NEUTRAL DRIFT VARIANT
NEUTRALLY DRIFTING
NON-CONSENSUS
NON-CONSENSUS
NON-CONSENSUS VARIANT
NON-NEUTRALIZING
NON-NEUTRALIZING
NON-NEUTRALIZING FACE
NON-NEUTRALIZING FACE
NON-NEUTRALIZING FACE
NON-NEUTRALIZING FACE
NUCLEOTIDE SEQUENCE
OBSERVED DRIFT
OVERABUNDANCE
OVERABUNDANCE
OVERABUNDANCE
REPLACEMENT MUTATION OVERABUNDANCE
REPLACEMENT MUTATION OVERABUNDANCE
REPLACEMENT OVERABUNDANCE
PARAMETER SET
PARSIMONIOUS EXPLANATION
PER
PHYLOGENY
PHYLOGENY
PHYLOGENY
PHYLOGENY
PL
POINT MUTATION
TTT POINT MUTATION
POINT MUTATION
POLYCLONAL ANTI-SERA
POSITIONAL
POSITIVE PERCENTAGE
POSITIVE RATE
POSITIVE RATE
POSITIVE RATE
POSITIVE SELECTION
POSITIVE SELECTION
POSITIVE SELECTION
POSITIVE SELECTION
POSITIVE SELECTION
PRACTICAL ADVANTAGE
PRACTICAL LEVEL
PRE-ALIGNED
PRESENTATION
PRESSURE EXERTED
PRIMARY SELECTIVE FORCE
AFFECTING HA VARIATION PRIMARY SELECTIVE FORCE
PRINCIPAL SURFACE ANTIGEN
HUMAN           IMMUNODEFICIENCY VIRUS PRINCIPAL SURFACE ANTIGEN
PROTEIN
PROTEIN
PROTEIN
PROTEIN
PROTEIN POSITION
PROTEIN POSITION
PROVIDED SELECTION PRESSURE
RT QUASISPECIATION PROVIDED SELECTION PRESSURE
PUTATIVE ANTIGENIC SITE
QUASISPECIATION
QUASISPECIATION
REVERSE TRANSCRIPTASE QUASISPECIATION
QUASISPECIES SEQUENCE SPACE
QUASISPECIES--A SET
RECOGNIZING GP120 MOLECULE
RENDERED RT
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION TESTED
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
REPLACEMENT MUTATION
VARYING FITNESS REPLACEMENT MUTATION
REPLACEMENT POINT MUTATION
REPLACEMENT
RESPONSE STRENGTH
REVERSE TRANSCRIPTASE
SEASONAL INFLUENZA EPIDEMIC
SELECTED CODON
SELECTED GP120 VARIANT
SELECTED MUTATION
SELECTED MUTATION
SELECTED MUTATION
SELECTED MUTATION
SELECTED MUTATION
SELECTED MUTATION
VIRAL QUASISPECY SELECTED MUTATION
SELECTED REPLACEMENT MUTATION
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
SELECTED VARIANT
QUASI SELECTED VARIANT
REVERSE TRANSCRIPTASE SELECTED VARIANT
INFLUENZA SELECTED VARIANT
INFLUENZA SELECTED VARIANT
SPANNING ANTIGENIC SITE D SELECTED VARIANT
SELECTED VARIATION
SELECTION DETECTOR
SELECTION MAP
SELECTION MAP
SELECTION MAP
HEMAGGLUTININ SELECTION MAP
HIV-1 RT SELECTION MAP
GP120 SELECTION MAP
SELECTION MAPPED
SELECTION MAPPING
SELECTION MAPPING
SELECTION MAPPING
SELECTION MAPPING
SELECTION MAPPING
SELECTION MAPPING
SELECTION MAPPING METHOD
HUMAN           IMMUNODEFICIENCY VIRUS SELECTION MAPPING
SELECTION PRESSURE
SELECTION PRESSURE EXERTED
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
SELECTIVE ADVANTAGE
VIRAL VARIATION SELECTIVE ADVANTAGE
SELECTIVE EVENT
SELECTIVE FACTOR
SELECTIVE FORCE
AFFECTING HIV QUASISPECIATION SELECTIVE FORCE
SELECTIVE PRESSURE
SHAPING RT QUASISPECIATION SELECTIVE PRESSURE
SELECTIVE PRESSURE
SELECTIVE PRESSURE
SEQUENCE EVOLUTION
SEQUENCING
SERINE
SHAPING RT QUASISPECIATION
SHED GP120 MONOMER
SIGNIFICANCE
SIGNIFICANCE LEVEL
SIGNIFICANCE PROBLEM
SITE E
SITE EPITOPE
SPANNING ANTIGENIC SITE D
STOP CODON
STOP CODON
SURVEILLANCE
SYNTHETIC FOOT-AND-MOUTH DISEASE VIRUS VACCINE
TCT
TESTING PROCEDURE
TGT
TRIMER
TRIMER INTERFACE
TRIMER INTERFACE
TRIMER-BURIED PORTION
TRIMER-BURIED PORTION
HEMAGGLUTININ TRIMER-BURIED PORTION
ANTIGENIC SITE D TRIMER-BURIED PORTION
TTA
TTC
TTG
TTT
TTT
TTT
TTT
TTT
TTT CODON
TXT
TYROSINE
UNKNOWN
VALINE
VARYING FITNESS
VICE VERSA
VIRAL NUCLEOTIDE SEQUENCE
VIRAL POPULATION
VIRAL PROTEIN
VIRAL QUASISPECY
VIRAL QUASISPECY
VIRAL QUASISPECY
VIRAL QUASISPECIES MEMBER
VIRAL SEQUENCE
VIRAL SEQUENCE
VIRAL SUBPOPULATION
VIRAL VARIANT
VIRAL VARIANT
VIRAL VARIANT
VIRAL VARIATION
WWW
Î‘5-C
Î£MOST
HUMAN           IMMUNODEFICIENCY VIRUS
HIV
HA
ANTIBODIES
ABS
REVERSE TRANSCRIPTASE
RT
CD4-BINDING           SITE
CD4BS
CD4I
MAJOR HISTOCOMPATIBILITY           COMPLEX
MHC
RESISTANCE
RESISTANCE
AZT RESISTANCE
AZT RESISTANCE
RESISTANCE SELECTABLE
AB
PROTECTION
cellular cytotoxicity
ANTIGENIC
DRIFT
ANTIGENIC
DRIFT
B-CELL
B-CELL
B-CELL
B-CELL
B-CELL
ANTIGENIC DRIFT
CD4-BINDING
CD4-INDUCED
EPITOPE
mutations
HEMAGGLUTININ QUASI
HEMAGGLUTININ
SEROTYPE
SEROTYPE
HA T-CELL
T-CELL
HA ESCAPE
TRIMER
ANTIGENIC DRIFT
ANTIGENIC
HIV BREAKTHROUGH
STRAIN RF
RT
RT
RT
GP120
GP120
GP120
HIV-1 GP120
GP120
REVERSE TRANSCRIPTASE
mutations
NUCLEOTIDE
packages
ALGORITHM
ALGORITHM
tests
functions
mutations
QUASISPECIATION
SELECTION MAP
SELECTION
maps
SELECTION
maps
calculations
INFORMATION CONTENT
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL
T-CELL IMMUNITY ESCAPE
T-CELL
REPLACEMENT
advantages
HA VARIATION
HA
HIV QUASISPECIATION
HIV
alignments
gaps
alignments
treatments
ANTIGENIC
DRIFT
ANTIGENIC
DRIFT
ANTIGENIC SITE
SITE B
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC SITE
ANTIGENIC
ANTIGENIC
ANTIGENIC
ANTIGENIC
ANTIGENIC
ANTIGENIC
ANTIGENIC
ANTIGENIC
HA
DISTRIBUTION
examples
consensus
CODON
consensus
CODON
consensus
CODON
consensus
CODON
CODON
orders
REPLACEMENT
SURFACE GLYCOPROTEIN--THE
ESCAPE
ESCAPE
examples
cases
CODON
S
GP120
GP120
GP120
QUASISPECIATION
GP120
three-dimensional structure
GP120
TRIMER
HELPER T-CELL
helper
T-CELL
TH FRACTION
PHYLOGENY
MHC PRESENTATION
MHC
REPLACEMENT
VIRAL DIVERSITY
PHYLOGENY
AB
CODON
CODON
mutations
ratios
mutations
ratios
SELECTION
SELECTION
SELECTION
SELECTION
JUKES-CANTOR EVOLUTION
JUKES-CANTOR
DRIFT
DRIFT
DRIFT
DRIFT
DRIFT
DRIFT
DRIFT
DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NEUTRAL DRIFT
NON-CONSENSUS
NON-NEUTRALIZING
faces
NON-NEUTRALIZING
faces
NON-NEUTRALIZING
faces
NON-NEUTRALIZING
faces
DRIFT
explanations
mutations
ANTI-SERA
SELECTION
SELECTION
SELECTION
SELECTION
SELECTION
advantages
pressures
SELECTIVE FORCE
SURFACE ANTIGEN
positions
SELECTION PRESSURE
RECOGNIZING GP120
GP120
RT
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT
mutations
REPLACEMENT MUTATION
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
REPLACEMENT
responses
strengths
TRANSCRIPTASE
SEASONAL INFLUENZA
SELECTED GP120
GP120
SELECTED REPLACEMENT
variants
variants
variations
SELECTION
SELECTION
maps
SELECTION
maps
SELECTION
maps
SELECTION
SELECTION
SELECTION
SELECTION
SELECTION
SELECTION
SELECTION
SELECTION
SELECTION
pressures
SELECTION PRESSURE
SELECTION
advantages
advantages
advantages
advantages
advantages
advantages
advantages
advantages
advantages
events
FACTOR
pressures
evolution
RT QUASISPECIATION
RT
SHED GP120
GP120
SIGNIFICANCE
SIGNIFICANCE
problems
ES
EPITOPE
ANTIGENIC
stops
stops
portions
portions
CODON
VERSA
populations
QUASISPECIES MEMBER
variations
